
    
      This clinical trial is a randomized Phase 2 evaluation of CB-839 (telaglenastat) in
      combination with cabozantinib versus placebo with cabozantinib in Renal Cell Carcinoma
      patients with at least one and not more than 2 prior therapies in the advanced or metastatic
      setting.
    
  